US2014336383A1PendingUtilityA1

Prolyl hydroxylase inhibitors

67
Assignee: GLAXOSMITHKLINE LLCPriority: Jun 23, 2006Filed: Jul 18, 2014Published: Nov 13, 2014
Est. expiryJun 23, 2026(expired)· nominal 20-yr term from priority
Inventors:Duke M. FitchAntony N. ShawKenneth Wiggall
A61P 7/06A61P 9/10A61P 43/00A61P 7/00A61P 9/00C07D 417/10C07D 239/62C07D 239/60C07D 401/04C07D 405/10C07D 413/06C07D 409/10A61K 31/515C07D 239/22C07D 413/10C07D 409/04C07D 239/54C07D 405/04A61K 31/47C07D 487/08A61K 31/495
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . The compound ethyl N-[(1,3-dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycinate or a salt thereof. 
     
     
         2 . The compound ethyl N-[(1,3-dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycinate.

Join the waitlist — get patent alerts

Track US2014336383A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.